factual
Biotech VC Targets 3-4x Returns, Not Power Law
Unlike tech venture capital, where a 1000-to-1 upside lets investors win only 1 in 100, biotech venture returns are not gigantic: a 10x return is wonderful and rare, and the target is 3 to 4x, with 5x a great outcome, so biotech investors cannot afford to be wrong as often.
factualpending
Speaker
Tal ZaksEvidence Quote
“Our returns are not gigantic. To get a 10x return for us is wonderful, not something you see commonly. And to get a larger than 10x return is rare. So we shoot for 3 to 4x returns.”
Created: 11/19/2026, 4:01:33 PM
Your notes
Loading notes...